创新驱动未来 Innovation Drives Future

佰睿壹生物 Bio-reinnovation

用技术创新构建ADC的未来 Building the Future of ADC with Innovation

佰睿壹生物专注于抗体偶联药(ADC)的底层技术创新和下一代ADC药物的研发，致力于为全球患者带来突破性的治疗方案。 Bio-reinnovation focuses on fundamental technological innovation in Antibody-Drug Conjugates (ADC) and the development of next-generation ADC therapeutics, committed to bringing breakthrough treatments to patients worldwide.

OUR COMPANY 关于我们

佰睿壹生物专注于抗体偶联药(ADC)的底层技术创新和双载荷ADC药物开发。作为抗体链间二硫键选择性还原技术的开拓者，我们开发了系统性化学定点偶联技术平台MCLICK，该平台能够实现非常多样的ADC DAR值和双载荷ADC的比例，支持单载荷AXC和双载荷ADC的精细化设计。同时，抗体链间二硫键选择性还原/偶联的技术路径具有卓越的兼容性、广泛的适用性和明确且非常友好的CMC成本优势，是赋能First-in-Class和Best-in-Class ADC差异化创新的强大工具。 Bio-reinnovation focuses on fundamental technological innovation in Antibody-Drug Conjugates (ADC) and the development of dual-payload ADC drugs. As a pioneer of interchain disulfide bond selective reduction technology, we have developed the systematic site-specific chemical conjugation platform MCLICK, which enables highly diverse ADC DAR values and dual-payload ADC ratios, supporting the precise design of both single-payload AXC and dual-payload ADCs. Meanwhile, the interchain disulfide bond selective reduction/conjugation approach offers excellent compatibility, broad applicability, and clear, highly favorable CMC cost advantages, making it a powerful tool to empower First-in-Class and Best-in-Class ADC differentiated innovation.

用技术创新构建ADC的未来 Building the future of ADC with innovation

技术平台简介 Technology Platform Introduction

佰睿壹生物ADC创新技术平台包括化学定点偶联技术平台MCLICK™、亲水性连接子-毒素技术平台HILT、超低DAR值AXC技术平台UDAC和双载荷ADC技术平台DPAC。其中MCLICK™由一揽子化学定点偶联技术组成，可以实现IgG1类单、双抗从1到8任意DAR值的AXC定点定量偶联。通过不同技术的组合，MCLICK™还能用于双载荷或者多载荷ADC的制备，可以实现两种或者三种不同作用机制药物分子的偶联和比例的灵活调节。 Bio-reinnovation's ADC innovation platforms include the chemical site-specific conjugation platform MCLICK™, the hydrophilic linker-toxin platform HILT, the ultra-low DAR AXC platform UDAC, and the dual-payload ADC platform DPAC. Among them, MCLICK™ consists of a suite of chemical site-specific conjugation technologies, enabling site-specific and quantitative conjugation of IgG1 monoclonal and bispecific antibodies with any DAR value from 1 to 8. By combining different technologies, MCLICK™ can also be used for the preparation of dual- or multi-payload ADCs, allowing flexible conjugation and ratio adjustment of two or three payloads with different mechanisms of action.

技术优势 Technical Advantages

ADC领域痛点 ADC Challenges

单载荷ADC耐药性问题 Resistance in Single-Payload ADCs
收率较低、酶催化偶联技术导致工艺成本较大 Low Yield and High Process Costs with Enzyme-Catalyzed Conjugation
双载荷ADC可选DAR值较为单一 Limited DAR Options in Dual-Payload ADCs
传统巯基偶联技术的不足 Limitations of Traditional Thiol Conjugation

佰睿壹优势 Our Advantages

双载荷ADC可解决耐药性问题 Dual-Payload ADCs Address Resistance
巯基化学定点偶联技术，大幅降低CMC成本 Site-Specific Thiol Conjugation Reduces CMC Costs
最丰富的的双载荷ADC可选DAR值比例 Most Diverse DAR Ratio Options for Dual-Payload ADCs

Bio-Reinno系统性化学定点偶联平台——MCLICK Bio-Reinno Systematic Site-specific Chemical Conjugation Platform -- MCLICK

MCLICK平台支持多种DAR值及双载荷ADC比例的灵活定制，满足复杂药物设计需求。 The MCLICK platform supports flexible customization of various DAR values and dual-payload ADC ratios to meet complex drug design needs.

ADC DARADC DAR	双载荷ADC比例Dual-Payload ADC Ratio
DAR1	DAR1+DAR1, DAR1+DAR2, DAR1+DAR4, DAR1+DAR6
DAR2	DAR2+DAR1, DAR2+DAR2, DAR2+DAR4, DAR2+DAR6
DAR4	DAR4+DAR1, DAR4+DAR2, DAR4+DAR4
DAR6	DAR6+DAR1, DAR6+DAR2

基于链间二硫键高度选择性还原Highly selective interchain disulfide bond reduction

兼容所有巯基反应性LDCompatible with all thiol-reactive LDs

DAR值选择丰富，均一性高Rich DAR options and high homogeneity

双载荷ADC比例调节灵活性高Highly flexible dual-payload ADC ratio adjustment

适用多种IgG1工程化抗体骨架Applicable to various IgG1 engineered antibody scaffolds

工艺简洁稳健，成本友好Simple, robust process and cost-effective

技术对照 Technology Comparison

佰睿壹生物MCLICK™技术与其他常见偶联方法的对比概述，突出其在灵活性、成本效益以及对先进ADC设计的适用性方面的优势。 Comparison of Bio-Reinno MCLICK™ technology with other common conjugation methods, highlighting its advantages in flexibility, cost-effectiveness, and suitability for advanced ADC design.

关键特性Key Feature	MCLICK™ （佰睿壹）(Bio-Reinno)	传统巯基（示例）Traditional Thiol (Example)	酶介导（示例）Enzyme-mediated (Example)
DAR灵活性(单/双载荷)DAR Flexibility (Mono/Dual)	✓	Limited	Moderate
无酶工艺Enzyme-free Process	✓	✓	✗
抗体兼容性Antibody Compatibility	Excellent	Good	Variable
CMC成本效益CMC Cost Efficiency	High	Moderate	Lower
多载荷适用性Multi-payload Applicability	✓	✗	Limited

产品管线 Product Pipeline

我们的双有效载荷ADC管线经过精心设计，通过创新的MOA组合，针对高发病率、异质性强、耐药性高的肿瘤，显著拓展适应症范围，提升疗效。通过克服TOP1耐药、优于单载荷ADC，并与免疫治疗协同，致力于为患者带来更优治疗选择，解决未满足的医疗需求。 Our dual payload ADC pipeline is carefully designed and leverages innovative MOA combinations to address tumors with high incidence, strong heterogeneity, and significant drug resistance. This approach broadens indications and enhances efficacy by overcoming TOP1i resistance, outperforming mono-payload ADCs, and achieving better synergy with immunotherapy, aiming to provide superior treatment options for patients and address unmet medical needs.

✓ 更丰富的作用机制（MOA）
✓ 克服耐药性
✓ 克服肿瘤异质性
✓ 增强ICD效应
✓ Richer MOA
✓ Overcoming drug resistance
✓ Overcoming tumor heterogeneity
✓ Enhancing ICD

载荷作用机制（MOA）

载荷1Payload 1	载荷2Payload 2
TOP1i	MTA
TOP1i	DDRi
MTA	MTA
MTA	DDRi

ADC/MOAADC/MOA	研发阶段Discovery	先导优化Lead Opt.	临床前Preclinical	临床验证Clinically Proven	适应症Indication
BP100101 TOP1i + MTA 适应症：胃癌, 结直肠癌, 胰腺癌 Indication: GC, CRC, PAAD					胃癌, 结直肠癌, 胰腺癌GC, CRC, PAAD
BP100201 TOP1i + MTA 适应症：三阴性乳腺癌, 尿路上皮癌, 宫颈癌 Indication: TNBC, UC, CC					三阴性乳腺癌, 尿路上皮癌, 宫颈癌TNBC, UC, CC
BP100301 TOP1i + MTA 适应症：非小细胞肺癌, 转移性乳腺癌, 尿路上皮癌, 胃癌, 结直肠癌 Indication: NSCLC, mBC, UC, GC, CRC					非小细胞肺癌, 转移性乳腺癌, 尿路上皮癌, 胃癌, 结直肠癌NSCLC, mBC, UC, GC, CRC
BP100401 TOP1i + MTA 适应症：三阴性乳腺癌, 卵巢癌, 非小细胞肺癌 Indication: TNBC, OC, NSCLC					三阴性乳腺癌, 卵巢癌, 非小细胞肺癌TNBC, OC, NSCLC
BP100901 TOP1i + MTA 适应症：三阴性乳腺癌, 非小细胞肺癌, 尿路上皮癌, 卵巢癌, 结直肠癌 Indication: TNBC, NSCLC, UC, OC, CRC					三阴性乳腺癌, 非小细胞肺癌, 尿路上皮癌, 卵巢癌, 结直肠癌TNBC, NSCLC, UC, OC, CRC